Concepedia
Statistics
Publications
7
Citations
417
H-Index
Active since
2016
Affiliations
Janssen (United States)(Current)
Icahn School of Medicine at Mount Sinai
University of California San Diego
Western University
Janssen Scientific Affairs (United States)
C Gasink is an author at Janssen (United States) specializing in inflammatory bowel disease, ustekinumab therapy, and pharmacotherapy.
Publications per year
2016–2023
Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
William J. Sandborn, P. Rutgeerts, C Gasink et al. · Alimentary Pharmacology & Therapeutics · 2018 · 182 citations · Full text
Pharmacy, Pharmacology, Pharmacotherapy +17
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
Subrata Ghosh, Lianne S. Gensler, Zijiang Yang et al. · Drug Safety · 2019 · 116 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +15
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
Amanda M. Johnson, Maria Barsky, Waseem Ahmed et al. · The American Journal of Gastroenterology · 2022 · 68 citations
Medicine, Clinical Sciences, Pharmacotherapy +15
P495 Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials
Laurent Peyrin‐Biroulet, Remo Panaccione, C Gasink et al. · Journal of Crohn s and Colitis · 2022 · 15 citations · Full text
OP010 Long term efficacy and safety of Ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through 2 years
William J. Sandborn, P. Rutgeerts, C Gasink et al. · Journal of Crohn s and Colitis · 2017 · 13 citations · Full text
Life Sciences, Immunology, Pharmacology +13
1–5 of 7